As the first commercial ventures are formed around induced pluripotent stem (iPS) cell research, who will have the freedom to operate commercially remains a big unknown. Sarah Webb reports.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Ebert, A.D. et al. Nature 457, 277–281 (2009).
Dimos, J.T. et al. Science 321, 1218–1221 (2008).
Soldner, F. et al. Cell 136, 964–977 (2009).
Lee, G. et al. Nature 461, 402–406 (2009).
Kim, D. et al. Cell Stem Cell 4, 472–476 (2009).
Lin, T. et al. Nature Methods, published online 18 October, 2009, doi10.1038/nmeth.1393.
Yu, J. et al. Science 324, 797–801 (2009).
Rights and permissions
About this article
Cite this article
Webb, S. The gold rush for induced pluripotent stem cells. Nat Biotechnol 27, 977–979 (2009). https://doi.org/10.1038/nbt1109-977
This article is cited by
The global intellectual property landscape of induced pluripotent stem cell technologies
Nature Biotechnology (2014)
LULL(ed) into complacency: a perspective on licenses and stem cell translational science
Stem Cell Research & Therapy (2013)
Burgeoning stem cell product market lures major suppliers
Nature Biotechnology (2010)